First Tracks Biotherapeutics Announces Participation in September Investor Conferences

About this update from First Tracks Biotherapeutics, Inc.

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences: 21 st Annual Wells Fargo Healthcare Conference, Boston Citi's 2026 Biopharma Back to School Conference, New York City Morgan Stanley 24th Annual Global Healthcare Conference, New York City A live webcast of the fireside chat will be available on the investor section of the First Tracks website at https://ir.firsttracksbio.com/news-events/events . A replay of the webcast will be available for at least 30 days following the event. About First Tracks Biotherapeutics First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn . Investor Contact: Nick Montemarano Vice President, Investor Relations 858.732.0178 [email protected]

View stock analysis, news, and events for First Tracks Biotherapeutics, Inc.